for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ionis Pharmaceuticals Inc

IONS.OQ

Latest Trade

62.71USD

Change

-0.23(-0.37%)

Volume

828,576

Today's Range

62.02

 - 

63.39

52 Week Range

43.27

 - 

86.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
62.94
Open
62.98
Volume
828,576
3M AVG Volume
22.42
Today's High
63.39
Today's Low
62.02
52 Week High
86.55
52 Week Low
43.27
Shares Out (MIL)
140.50
Market Cap (MIL)
8,810.77
Forward P/E
-829.50
Dividend (Yield %)
--

Next Event

Q3 2019 Ionis Pharmaceuticals Inc Earnings Release

Latest Developments

More

Ionis Licenses Hepatitis B Program To GSK

Ionis Reports Second Quarter 2019 Financial Results

Ionis Reports Q1 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Industry

Biotechnology & Drugs

Contact Info

2855 Gazelle Ct

+1.760.9319200

http://www.ionispharma.com/

Executive Leadership

Stanley T. Crooke

Chairman of the Board, President, Chief Executive Officer

Elizabeth L. Hougen

Senior Vice President, Finance and Chief Financial Officer

Brett P. Monia

Chief Operating Officer and Senior Vice President, Translational Medicine, Director

Patrick R. O'Neil

Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary

C. Frank Frank Bennett

Senior Vice President - Antisense Research

Key Stats

2.81 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.3K

2017

0.5K

2018

0.6K

2019(E)

0.8K
EPS (USD)

2016

-0.720

2017

-0.050

2018

2.070

2019(E)

-0.076
Price To Earnings (TTM)
21.88
Price To Sales (TTM)
11.03
Price To Book (MRQ)
6.94
Price To Cash Flow (TTM)
23.36
Total Debt To Equity (MRQ)
51.95
LT Debt To Equity (MRQ)
50.97
Return on Investment (TTM)
16.79
Return on Equity (TTM)
14.17

Latest News

EU committee approves Akcea-Ionis drug for rare genetic disease

An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood.

Novartis aims to pump up cardio business with Ionis deal

Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.

BRIEF-Ionis Pharmaceuticals - Announced Partner Roche, also known as Genentech In U.S., enrolled first patient in study of Rg6042 for Huntington's disease

* IONIS PHARMACEUTICALS - ANNOUNCED PARTNER ROCHE, ALSO KNOWN AS GENENTECH IN U.S., ENROLLED FIRST PATIENT IN STUDY OF RG6042 FOR HUNTINGTON'S DISEASE

BRIEF-Ionis Pharmaceuticals Enters New Collaboration With Partner

* IONIS ENTERS NEW COLLABORATION WITH PARTNER TO DEVELOP IONIS-FB-L RX FOR COMPLEMENT-MEDIATED DISEASES

Akcea Therapeutics genetic disease treatment gets FDA approval

Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

FDA declines to approve Akcea-Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

U.S. FDA declines to approve Akcea/Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease which causes fat accumulation in the blood.

BRIEF-Ionis Reports Q1 Total Revenue Of $144 Mln Vs $116 Mln

* FOR Q1 OF 2018, BASIC AND DILUTED NET LOSS PER SHARE WERE $0.01 Source text for Eikon: Further company coverage:

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES

Biogen to pay $1 billion to Ionis in new partnership

Drugmaker Biogen Inc said on Friday it would pay Ionis Pharmaceuticals Inc $1 billion in cash as part of a new ten-year agreement to develop medicines for a broad range of neurological diseases including dementia.

Ionis may get up to $300 million in licensing deal with AstraZeneca

Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

Ionis to get up to $300 mln from licensing deal with AstraZeneca

Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties.

BRIEF-Ionis And AstraZeneca Advance New Drug For NASH

* IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX

UPDATE 2-Pfizer's rare heart disease drug succeeds in late-stage study

* Brokerage Suntrust estimates sales of $130 mln of drug in 2022

BRIEF-Ionis Pharmaceuticals Reports Q4 Earnings Per Share of $0.02

* IONIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Ionis Pharmaceuticals - Qtrly Earnings Per Share $0.02

* IONIS PHARMACEUTICALS - QTRLY TOTAL REVENUE $172.3 MILLION VERSUS $160.3 MILLION

BRIEF-Ionis Licences New Antisense Drug For Kidney Disease To Astrazeneca

* IONIS LICENCES NEW ANTISENSE DRUG FOR KIDNEY DISEASE TO ASTRAZENECA

BRIEF-Ionis Pharmaceuticals Announces Initiation Of Clinical Study Of First Orally Delivered Antisense Drug For Treatment Of Gastrointestinal Disorders

* IONIS PHARMACEUTICALS ANNOUNCES THE INITIATION OF A CLINICAL STUDY OF ITS FIRST ORALLY DELIVERED ANTISENSE DRUG FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

BRIEF-Ionis' License Agreement For Huntington's Disease Drug Receives Hart-Scott-Rodino Clearance

* IONIS' LICENSE AGREEMENT FOR HUNTINGTON'S DISEASE DRUG, IONIS-HTT RX, RECEIVES HART-SCOTT-RODINO CLEARANCE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up